MedTrace Logo

Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer

NCT00496509 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2016-08-26

No results posted yet for this study

Summary

A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients with Advanced Colorectal Cancer and Liver Metastases.

Conditions

Interventions

DRUG

ZD6474 (Zactima) 100mg

PROCEDURE

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)

PROCEDURE

Biomarker Draws

DRUG

ZD6474 (Zactima) 300mg

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Clinical Sciences & Operations · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00496509 on ClinicalTrials.gov